SSY Group Limited announced that the Group's Formoterol Fumarate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Formoterol Fumarate is mainly used in the relief of symptoms such as difficulty in breathing caused by bronchial asthma, bronchitis (acute, chronic or asthmatic) and emphysema. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.